CStone to unveil key clinical data at ESMO 2025

CStone Pharmaceuticals will present new clinical advancements at ESMO 2025, including first-in-human Phase Ia data for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody. This marks the initial public disclosure of CS2009's clinical data.

CStone will also detail the global multicenter Phase Ib study design for CS5001, a ROR1-targeting antibody-drug conjugate. CS5001 has shown antitumor activity in lymphomas and solid tumors.